×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATOS – atossa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATOS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
08:19 am
atos
Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
High
Report
Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
3/26
12:54 am
atos
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
High
Report
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
3/25
06:10 pm
atos
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
High
Report
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/25
05:30 pm
atos
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
High
Report
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
3/19
08:00 am
atos
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Low
Report
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
3/12
08:21 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
3/12
08:00 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Low
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
2/11
08:30 am
atos
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
High
Report
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/25
05:21 pm
atos
Form 10-K ATOSSA THERAPEUTICS, For: Dec 31
High
Report
Form 10-K ATOSSA THERAPEUTICS, For: Dec 31
3/25
05:20 pm
atos
Form 8-K ATOSSA THERAPEUTICS, For: Mar 25
High
Report
Form 8-K ATOSSA THERAPEUTICS, For: Mar 25
3/20
04:52 pm
atos
Form PRE 14A ATOSSA THERAPEUTICS, For: Mar 20
Medium
Report
Form PRE 14A ATOSSA THERAPEUTICS, For: Mar 20
2/20
04:22 pm
atos
Form 8-K ATOSSA THERAPEUTICS, For: Feb 19
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Feb 19
2/20
04:16 pm
atos
Form 424B5 ATOSSA THERAPEUTICS,
Medium
Report
Form 424B5 ATOSSA THERAPEUTICS,
2/20
04:07 pm
atos
Form 424B3 ATOSSA THERAPEUTICS,
Medium
Report
Form 424B3 ATOSSA THERAPEUTICS,
2/17
04:32 pm
atos
Form 8-K ATOSSA THERAPEUTICS, For: Feb 17
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Feb 17
2/11
08:46 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Feb 11
High
Report
Form 8-K ATOSSA THERAPEUTICS, For: Feb 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
22.9%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
TOP News Decliners
4/16
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
-26.0%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: